HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Golbe, L. I. Search for Related Content PubMed PubMed Citation Articles by Golbe, L. I.

Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease

Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ.

Twenty-two patients with advanced Parkinson's disease whose symptom fluctuations had initially responded to deprenyl supplementation were followed for 19 to 27 months on that drug. The improvement disappeared in most cases after a mean of 7–8 months but persists at latest follow-up in 5 patients. Transient or continuing abnormalities in liver function tests occurred in 9 patients.

Address correspondence and reprint requests to Dr. Golbe, Department of Neurology, UMDNJ-Robert Wood Johnson Medical School, CN-19, New Brunswick, NJ 08903.

Somerset Pharmaceuticals, Inc., Denville, NJ, kindly supplied deprenyl tablets and financial support for data analysis.

Presented in part at the fortieth annual meeting of the American Academy of Neurology, Cincinnati, OH, April 1988.

Received January 4, 1989. Accepted for publication in final form March 1, 1989.

This article has been cited by other articles:

				C. H. Waters and J. J. Chen Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off'' Journal of Pharmacy Practice, August 1, 2008; 21(4): 254 - 261. [Abstract] [PDF]

				S. Horn and M. B. Stern The comparative effects of medical therapies for Parkinson's disease Neurology, October 12, 2004; 63(7_suppl_2): S7 - S12. [Full Text]

				The Parkinson Study Group Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease N. Engl. J. Med., January 21, 1993; 328(3): 176 - 183. [Abstract] [Full Text]

				B. G. Pollock, J. M. Perel, and C. F. Reynolds Pharmacodynamic Issues Relevant to Geriatric Psychopharmacology J Geriatr Psychiatry Neurol, October 1, 1990; 3(4): 221 - 228. [PDF]